Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 11,444,055	$ 2,624,162
Investment securities – available for sale, at fair value	12,724,020	1,680,000
Accrued interest receivable on investment securities	54,440	4,008
Advances and deposits on clinical programs	89,186	89,186
Other current assets		115,222
Total current assets	24,311,701	4,512,578
Property and equipment (at cost, less accumulated depreciation and amortization)	175,771	462,836
Other assets:
In-process research and development	20,246,491	22,766,491
Goodwill	1,976,101	1,976,101
Other intangible assets, net	795,608	1,022,924
Security deposit on letter of credit		100,000
Other assets	8,761	8,761
Total other assets	23,026,961	25,874,277
Total assets	47,514,433	30,849,691
Current liabilities:
Accounts payable - trade	3,416,863	2,878,978
Other accrued liabilities	2,282,827	2,483,756
Notes payable - current portion		2,560,553
Deferred revenue – current portion	500,000	500,000
Total current liabilities	6,199,690	8,423,287
Earn-out milestone liability	12,538,525	13,188,226
Deferred revenue – non-current portion	2,000,000	2,500,000
Other liabilities – non-current	71,710	12,352
Total liabilities	20,809,925	24,123,865
Commitments and contingencies
Stockholders’ equity:
Preferred Stock - $0.01 par value (100,000 shares authorized and no shares issued or outstanding at December 31, 2017 and 2016)
Common stock - $0.01 par value (112,500,000 shares authorized; 17,277,299 and 2,230,452 shares issued at December 31, 2017 and 2016, respectively, and 17,276,965 and 2,230,118 shares outstanding at December 31, 2017 and 2016, respectively)	172,772	22,305
Additional paid-in capital	288,408,976	248,168,421
Accumulated other comprehensive loss	(10,164)
Accumulated deficit	(261,781,888)	(241,379,712)
Total stockholders’ equity before treasury stock	26,789,696	6,811,014
Treasury stock, at cost (334 shares at December 31, 2017 and 2016)	(85,188)	(85,188)
Total stockholders’ equity	26,704,508	6,725,826
Total liabilities and stockholders’ equity	$ 47,514,433	$ 30,849,691